Insmed Incorporated (INSM) was a big mover last session, as the company saw its shares rise nearly 43% on the day. The share price surged after the Food and Drug Administration granted Arikayce, its lead investigational drug, breakthrough therapy designation.The move came on solid volume too with far more shares changing hands than in a normal session.This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $12.10 to $13.97 over the past one-month time frame.

None of the estimates for this stock were revised over the last 7 days. The Zacks Consensus Estimate also remained unchanged over the same time frame. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Insmed Incorporated carries a Zacks Rank # 3 (Hold), while its Earnings ESP is 0.00%

However, some better-ranked stocks in the Med-Biomed/Gene industry include Actelion Ltd. (ALIOF), ANI Pharmaceuticals, Inc. (ANIP) and Gilead Sciences Inc. (GILD). All of these stocks sport a Zacks Rank # 1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

INSMED INC (INSM): Free Stock Analysis Report

ACTELION LTD (ALIOF): Free Stock Analysis Report

ANI PHARMACEUTICALS INC (ANIP): Free Stock Analysis Report

GILEAD SCIENCES INC (GILD): Free Stock Analysis Report


Zacks Investment Research